Momenta Pharmaceuticals, Inc. (MNTA) Receives Consensus Rating of “Hold” from Analysts
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has been assigned a consensus rating of “Hold” from the eleven brokerages that are presently covering the company. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $16.60.
A number of equities research analysts recently commented on the stock. Aegis restated a “hold” rating and set a $17.00 price objective on shares of Momenta Pharmaceuticals in a report on Monday, February 6th. Maxim Group set a $6.00 price objective on shares of Momenta Pharmaceuticals and gave the stock a “sell” rating in a report on Wednesday, May 3rd. Leerink Swann lowered shares of Momenta Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 price objective on the stock. in a report on Tuesday, February 21st. Stifel Nicolaus dropped their price objective on shares of Momenta Pharmaceuticals from $30.00 to $26.00 and set a “buy” rating on the stock in a report on Wednesday, May 3rd. Finally, Cowen and Company restated a “hold” rating and set a $15.00 price objective on shares of Momenta Pharmaceuticals in a report on Wednesday, May 3rd.
In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 4,116 shares of Momenta Pharmaceuticals stock in a transaction on Friday, May 19th. The shares were sold at an average price of $15.83, for a total value of $65,156.28. Following the sale, the president now directly owns 281,919 shares in the company, valued at approximately $4,462,777.77. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 8,379 shares of company stock worth $131,825 over the last quarter. Company insiders own 6.10% of the company’s stock.
A number of large investors have recently modified their holdings of MNTA. Comerica Bank raised its stake in shares of Momenta Pharmaceuticals by 7.6% in the fourth quarter. Comerica Bank now owns 68,223 shares of the biotechnology company’s stock valued at $1,098,000 after buying an additional 4,817 shares during the last quarter. Two Sigma Investments LP acquired a new stake in shares of Momenta Pharmaceuticals during the fourth quarter valued at about $685,000. Russell Investments Group Ltd. acquired a new stake in shares of Momenta Pharmaceuticals during the fourth quarter valued at about $284,000. FMR LLC raised its stake in shares of Momenta Pharmaceuticals by 0.6% in the fourth quarter. FMR LLC now owns 10,679,748 shares of the biotechnology company’s stock valued at $160,730,000 after buying an additional 68,356 shares during the last quarter. Finally, Tocqueville Asset Management L.P. raised its stake in shares of Momenta Pharmaceuticals by 4.2% in the first quarter. Tocqueville Asset Management L.P. now owns 275,768 shares of the biotechnology company’s stock valued at $3,682,000 after buying an additional 11,050 shares during the last quarter. Hedge funds and other institutional investors own 84.44% of the company’s stock.
Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) traded down 0.167% during mid-day trading on Friday, reaching $14.975. The company had a trading volume of 65,402 shares. The company’s 50-day moving average price is $14.58 and its 200-day moving average price is $14.93. Momenta Pharmaceuticals has a 52-week low of $9.66 and a 52-week high of $19.90. The company’s market capitalization is $1.06 billion.
Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings data on Tuesday, May 2nd. The biotechnology company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.63. Momenta Pharmaceuticals had a negative net margin of 93.75% and a negative return on equity of 26.55%. The business had revenue of $26.61 million for the quarter, compared to analyst estimates of $21.29 million. During the same period last year, the business posted ($0.35) earnings per share. The firm’s quarterly revenue was up 34.1% on a year-over-year basis. On average, analysts forecast that Momenta Pharmaceuticals will post ($1.45) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Momenta Pharmaceuticals, Inc. (MNTA) Receives Consensus Rating of “Hold” from Analysts” was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/05/26/momenta-pharmaceuticals-inc-mnta-receives-consensus-rating-of-hold-from-analysts.html.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.